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Abstract: 
Background: Studies have reported relationship between chronic Helicobacter pylori infection and coronary artery 
disease (CAD). The cytotoxin-associated gene A product (CagA) is an immunodominant protein which indicates 
infection with virulent H. pylori strains. Significant associations of CagA-positive H. pylori strains with coronary 
artery disorders have been widely reported. H. pylori is also known to produce different heat shock proteins (HSPs) 
which can stimulate the production of specific antibody against microbial proteins and capable of eliciting 
autoimmune reaction against human tissue expressing HSPs such as vascular endothelial cells. The objectives of 
this study are to investigate the association between H. pylori and CagA with coronary atherosclerosis and CAD, 
and to determine the possible role of H. pylori HSP60 protein in increasing the risk of CAD development.  
Methods: This study included 70 patients with stable angina and 70 age and gender-matched controls. Each group 
was evaluated by clinical history, physical examination, cardiac echocardiography (ECHO) and electrocardiography 
(ECG) with and without exercise. Fasting blood glucose, total cholesterol (TC), low density lipoprotein (LDL), high 
density lipoprotein (HDL) and triglycerides (TG) were estimated by automated enzymatic methods. H. pylori IgG, 
CagA IgG and HSP60 IgG were measured by enzyme-linked immunosorbent assay (ELISA) for both groups.                        
Results: The seroprevalence of H. pylori infection was high in both groups; 75.7% in case and 68.6% in control 
(p=0.346). Serum IgG levels were significantly higher for CagA (p=0.028) and HSP60 (p<0.001) in cases than in 
controls. There was significant association between H. pylori and CagA IgGs in cases (p=0.007) but no association 
in controls (p=0.700). Higher HSP60 IgG level was significantly associated with both positive H. pylori IgG 
(p<0.001) and CagA IgG (p<0.001) in cases but no significant association was found with H. pylori (p=0.815) or 
CagA (p=0.332) IgG levels in the control group. Serum values were significantly higher for TC (p<0.001), TG 
(p<0.001) and LDL (p=0.004) while value for HDL was significantly lower (p<0.001) in H. pylori IgG-positive 
subjects (case and control).                                            
Conclusion: There is serological evidence that H. pylori infection may pose a significant risk factor for CAD. Since 
H. pylori can be eliminated by specific treatment, this may be a good preventive approach for CAD. 
 
Key words: H. pylori, coronary artery disease, CagA, HSP60, serology. 
 
Received July 23, 2019; Revised October 27, 2019; Accepted October 28, 2019 
 
Copyright 2020 AJCEM Open Access. This article is licensed and distributed under the terms of the Creative Commons Attrition 4.0 
International License (http://creativecommmons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction 
in any medium, provided credit is given to the original author(s) and the source.   
 
Preuve sérologique d'association entre l'infection à 
Helicobacter pylori et la maladie coronarienne 
 
1EL-Ageery, S. M., *1,4Gouda, N. S., 2Fawzy, I. M., 3Bahy-Eldeen, A., et 3Mahmoud, R. 
 
1Département de microbiologie médicale et d'immunologie, Faculté de médecine, Université Mansoura, Égypte 
2Laboratoires centraux Mansoura, Département de pathologie clinique, Ministère de la santé, Égypte                
3Département de médecine interne, Faculté de médecine, Université Mansoura, Égypte                                
4Département de microbiologie médicale et d'immunologie, Faculté de médecine, Université Northern Border,                                                                            
Association of Helicobacter pylori with coronary artery disease    Afr. J. Clin. Exper. Microbiol. 2020; 21 (2): 88-96  
89 
 
  Royaume d'Arabie saoudite.     
 *Correspondance à: nawalsalama@gmail.com; 00966502933179 
Abstrait: 
Contexte: Des études ont montré un lien entre l’infection chronique à Helicobacter pylori et la maladie 
coronarienne. Le produit du gène A associé à la cytotoxine (CagA) est une protéine immunodominante qui indique 
une infection par des souches virulentes de H. pylori. Des associations significatives de souches de H. pylori CagA-
positives avec des troubles coronariens ont été largement rapportées. H. pylori est également connu pour produire 
différentes protéines de choc thermique (HSP) capables de stimuler la production d'anticorps spécifiques contre les 
protéines microbiennes et capables de provoquer une réaction auto-immune contre les HSP exprimant le tissu 
humain, telles que les cellules endothéliales vasculaires. Les objectifs de cette étude sont d'étudier l'association 
entre H. pylori et CagA avec l'athérosclérose coronarienne et la coronaropathie, et de déterminer le rôle possible de 
la protéine H. pylori HSP60 dans l'augmentation du risque de développement de coronaropathie.                     
Méthodes: Cette étude a inclus 70 patients présentant une angine de poitrine stable et 70 témoins de même âge 
et de même sexe. Chaque groupe a été évalué par antécédents cliniques, examen physique, échocardiographie 
cardiaque (ECHO) et électrocardiographie (ECG) avec et sans exercice. La glycémie à jeun, le cholestérol total 
(TC), les lipoprotéines de basse densité (LDL), les lipoprotéines de haute densité (HDL) et les triglycérides (TG) ont 
été estimés par des méthodes enzymatiques automatisées. Les IgG anti-H. pylori, IgG CagA et IgG HSP60 ont été 
mesurées par dosage immuno-enzymatique (ELISA) pour les deux groupes.                                             
Résultats: La séroprévalence de l'infection à H. pylori était élevée dans les deux groupes; 75,7% en cas et 68,6% 
en contrôle (p=0,346). Les taux sériques d'IgG étaient significativement plus élevés pour CagA (p=0,028) et 
HSP60 (p<0,001) chez les sujets témoins. Il y avait une association significative entre les IgG anti-H. pylori et 
CagA dans les cas (p=0,007), mais aucune association chez les témoins (p=0,700). Un taux plus élevé d’IgG 
HSP60 était associé de manière significative à la fois aux IgG positives pour H. pylori (p<0,001) et aux IgG anti-
CagA (p<0,001), mais aucune association significative n’a été constatée avec H. pylori (p = 0,815) ou CagA 
(p=0,332). Taux d'IgG dans le groupe témoin. Les valeurs sériques étaient significativement plus élevées pour le 
CT (p<0,001), le TG (p<0,001) et le LDL (p=0,004), tandis que les valeurs pour le HDL étaient significativement 
plus basses (p<0,001) chez les sujets positifs pour H. pylori IgG.                                     
Conclusion: Il existe des preuves sérologiques que l'infection à H. pylori peut constituer un facteur de risque 
significatif de coronaropathie. Étant donné que H. pylori peut être éliminé par un traitement spécifique, cela peut 
constituer une bonne approche préventive pour la coronaropathie. 
Mots clés: H. pylori, maladie coronarienne, CagA, HSP60, sérologie. 
Introduction: 
 
 Helicobacter pylori infection is one of 
the most widespread infections worldwide, 
affecting half the population of the world. The 
bacterium causes chronic gastritis, peptic ulcer 
and gastric cancer (1). The infection stimulates 
both cell mediated and humoral immune 
system with elevation of basophils and 
polymorphs (2), and increased concentration of 
local and systemic vasoactive cytokines (3). 
These reactions are not restricted to the 
digestive tract (4) but also involved many extra 
gastrointestinal manifestations including haem- 
atological disorders (idiopathic thrombocyto- 
penic purpura and unexplained iron deficiency 
anemia), neurological disorders (stroke, Par- 
kinson and Alzheimer’s diseases), obesity and 
skin diseases (5,6).  
Several studies have reported relation- 
ship between chronic H. pylori infection and 
coronary artery disease (CAD), highlighting its 
role in the pathogenesis of coronary vascular 
disorders (7).  The cytotoxin-associated gene A 
(CagA) product is an immunodominant protein 
which indicates infection with virulent H. pylori 
strains. Some studies have reported significant 
associations of CagA-positive H. pylori strains 
with coronary artery disorders (8).  
Helicobacter pylori have been detected 
in human atherosclerotic plaques by immuno- 
histochemistry and polymerase chain reaction 
(9), and particularly in patients undergoing 
coronary bypass grafting (10). Chronic H. 
pylori infection is believe to induce low-grade 
constant inflammatory response with release of 
mediators that causes vascular endothelial 
damage through recruitment of monocytes and 
T-lymphocytes to the vascular wall, even in the 
absence of the pathogen. Therefore, chronic H. 
pylori infection does not only induce coronary 
atherosclerosis but can activate acute coronary 
rupture (11).  
A variety of systemic effects including 
atherosclerosis can be induced by chronic 
infection in several different manners through 
increasing circulating cytokine (interleukins 1 
and 6) production and formation of the acute-
phase products such as C-reactive protein and 
white blood cells. Also, chronic infection can 
stimulate the immune system with production 
of antibodies against the infecting pathogen 
(12). Furthermore, pathogens can stimulate 
proliferation and migration of smooth muscle 
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cells, accumulation of lipid, and formation of 
several pro-coagulants, with inhibition of endo- 
thelial cell apoptosis (13).  
Heat shock proteins (HSPs) represent 
well conserved protein families sharing wide 
sequence homology amongst various species, 
from bacteria to humans (14). Exposure to 
stressful stimuli such as sudden increase in 
temperature, hypoxia, infection, inflammation, 
mechanical stress, and oxidizing agents can 
induce or up-regulate production of HSPs (14). 
These proteins play essential roles in the 
bacterial growth at different temperatures and 
protection against a variety of injurious factors 
(15). H. pylori are known to produce different 
HSPs that stimulate the production of specific 
antibodies (16). Due to high sequence homo- 
logy of HSPs, autoimmune reaction directed 
against bacterial HSPs as well as human (such 
as vascular endothelium) HSPs, could occur 
(17).     
 The objectives of this study are to;                  
(i) determine association between H. pylori and 
CagA protein with CAD; (ii) investigate the 
possible role of H. pylori in CAD by estimating 
its specific HSP60 IgG levels in patients with 
CAD and healthy subjects and (iii) determine 
association between H. pylori and known risk 
factors for CAD.  
Methodology: 
 
Subjects (case and control) 
This case control study was conducted 
over a period of six months (January to June 
2019), and included 70 patients (cases) with 
stable angina selected by stratified random 
sampling among patients admitted to the 
cardiology unit or attending the cardiology out- 
patient clinic of Mansoura University Hospital, 
Egypt. Clinical history, physical examination, 
cardiac echocardiography (ECHO), and electro- 
cardiography (ECG) with and without exercise, 
were done for each subject. The cases had 
signs and symptoms of angina at exercise ECG 
with more than 2mm ST segment depression. 
The controls were 70 age and gender-matched 
patients randomly selected from units other 
than cardiology who had no feature of CAD 
(negative tread mill test).  
 
Exclusion criteria  
The exclusion criteria for both case and 
control subjects were; (i) significant kidney 
insufficiency (creatinine more than 1.5 mg/dL), 
(ii) significant hypothyroidism/hyperthyroidism 
(serum thyroid stimulating hormone level more 
than 4.5IU/mL or free thyroxine more than             
2ng/dL), (iii) significant C-reactive protein 
elevation (more than 10mg/L) and (iv) persons 
with any history of intake of antibiotics for H. 
pylori infection during the last 3months. 
 
Ethical approval 
The study was approved by Institu- 
tional Review Board of the Faculty of Medicine, 
Mansoura University, Egypt. All subject partici- 
pants gave informed consent for the study. 
 
Clinical and laboratory evaluations of case and 
control subjects    
 Subjects in both groups were eva- 
luated for hypertension (indicated by systolic 
blood pressure ≥140mmHg, diastolic blood 
pressure of ≥90mmHg (or antihypertensive 
medication), body mass index (BMI), and 
smoking (patients who had stopped smoking 
for 10years or less were classified as smokers). 
Approximately 10ml of venous blood was colle-
cted from each subject with the serum 
separated and stored in aliquots at -80°C until 
specific tests were done. 
 
Determination of serum glucose and lipids 
 Fasting blood glucose (FBG), total 
cholesterol (TC), low density lipoprotein (LDL), 
high density lipoprotein (HDL) and triglycerides 
(TG) were measured by enzymatic methods in 
an automated chemistry analyzer (Toshiba 
TBA-120 FR, Toshiba Medical Systems, Japan) 
 
Determination of H. pylori infection IgG 
 The level of serum IgG to H. pylori O 
antigen was determined by a commercial 
enzyme-linked immunosorbent assay (ELISA) 
(Euroimmun, Germany). The value of upper 
limit of normal range for H. pylori specific IgG 
level for the assay kit is 22units/mL. 
 
Determination of H. pylori CagA IgG 
 The level of serum IgG to H. pylori 
CagA protein was serologically detected by a 
commercial ELISA assay (Radim Diagnostics, 
Germany). The value of upper limit of normal 
range for H. pylori CagA specific IgG levels for 
the assay kit is 15units/mL. 
 
Determination of H. pylori HSP60 IgG 
 The level of serum IgG to H. pylori 
HSP60 was serologically detected by a comm- 
ercial ELISA assay (Elabscience Biotechnology, 




 Statistical analysis was performed with 
the Statistical Package for the Social Sciences 
software version 17.0 (SPSS Inc., Chicago, IL, 
USA). The association between two variables 
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was evaluated using Chi-square or Fisher Exact 
tests for categorical variables and Student t 





 This study was conducted on 70 pati- 
ents who had stable angina, with mean age of 
58.9 years, and 70 controls with a comparable 
mean age of 57.7 years (p=0.426). The cases 
(36 males, 34 females) were gender-matched 
with the controls (40 males, 30 females) 
(p=0.497). The mean BMI of cases and 
controls were 30.4 and 29.8 respectively 
(p=0.251). There were no significant differ- 
rences between the case and control subjects 
regarding history of smoking (p=0.319), 
hypertension (p=0.122), diabetes mellitus 
(p=0.231) or fasting blood glucose (p=0.074).  
 The prevalence of H. pylori infection 
was 75.7% in the case and 68.6% in control 
subjects (p=0.346). On the other hand, CagA 
IgG (p=0.028) and HSP60 IgG (p<0.001) 
values were significantly higher in cases than 
in controls (Table 1). 
 
 
Table 1: Comparison of demographic and clinical data of case and control subjects 
Parameter  Control (n=70) Case (n=70) p value 
Age (years) Mean ± SD 57.7 ± 9.2 58.9±9.6 0.426 




n (%) 40 (57.1) 36 (51.4) 0.497 
n (%) 30 (42.9) 34 (48.6) 
BMI (kg/m2) Mean ± SD 29.8 ±3.0 30.4±3.5 0.251 
Smoking n (%) 14 (20.0) 19 (27.1) 0.319 
DM n (%) 14 (20.0) 22 (31.4) 0.122 
FBG (mg/dL) Median (range) 107.5 (78 -256) 110.5 (85-350) 0.074 
Hypertension n (%) 26 (37.1) 33 (47.1) 0.231 
Helicobacter pylori IgG n (%) 48 (68.6) 53 (75.7) 0.346 
CagA IgG n (%) 31 (44.3) 44 (62.9) 0.028* 
HSP60 IgG Median (range) 839 (550-4837) 3365 (1187-5298) <0.001* 
* = significant difference 
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  Table 2: Association of CagA IgG with Helicobacter pylori IgG in case and control subjects 
 Control (n=70) p value Case (n=70) p value 
H. pylori IgG 
negative (n=22) 
H. pylori IgG 
positive (n=48) 
H. pylori IgG 
negative (n=17) 
H. pylori IgG 
positive (n=53) 
CagA IgG Negative n (%) 13 (59.1) 26 (54.2) 0.700 11 (64.7) 15 (28.3) 0.007* 
Positive n (%) 9 (40.9) 22 (45.8) 6 (35.3) 38 (71.7) 
* = significant difference 
 









Negative Positive Negative Positive
Control Cases
H. pylori IgG
CagA IgG Negative CagA IgG Positive
 
 There was significant association of H. 
pylori and CagA IgGs in the case (p=0.007) 
but no such association in the control 
(p=0.700) (Table 2 and Fig 1). Higher anti-
HSP60 antibodies level was significantly 
associated with positive H. pylori IgG 
(p<0.001) and CagA IgG (p<0.001) in the 
case but no significant association was found 
with H. pylori IgG (p=0.815) or CagA IgG 
(p=0.332) in the control group (Table 3, Figs 2 
and 3). The serum levels were significantly 
higher for TC (p<0.001), TG (p<0.001), and 
LDL (p=0.004) in H. pylori IgG-positive than H. 
pylori IgG-negative subjects (case and control) 
while HDL value was significantly lower 
(p<0.001) in H. pylori IgG-positive subjects 
(Table 4). 
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Table 3: Association of HPS60 IgG with H. pylori and Cag A IgGs in case and control subjects 
 Control (n=70) p value Case (n=70) p value 
H. pylori IgG 
negative (n=22) 
H. pylori IgG 
positive (n=48) 
H. pylori IgG 
negative (n=17) 
H. pylori IgG 
positive (n=53) 
HSP60 IgG Median 962.5 794 0.815 2698 3658 <0.001* 
Range 550-4398 550-4837 1187-3827 1187-5298 









HSP60 IgG Median 839 1445 0.332 2765 3876 <0.001* 
Range 550-4398 560-4837 1187-3265 1576-5298 
* = significance difference  
 
 
Fig. 2: Association of HPS60 IgG with H. pylori IgG in case and control subjects 
 
Fig 3: Association of HPS60 IgG with CagA IgG in case and control subjects 
 
Table 4: Association of Helicobacter pylori IgG with lipid profiles in case and control subjects 
Parameter 
 
Control (n= 70) Case (n= 70) 
H. pylori IgG 
negative              
(n= 22) 
H. pylori IgG 
positive (n= 48) 
p value H. pylori IgG 
negative (n=17) 
H. pylori IgG 
positive (n=53) 
p value 
median range median range median range median range 
TG (mg/dL) 50 42-76 125 76-234 <0.001 49 42-102 130 50-145 <0.001 
TC (mg/dL) 116 94-
195 
160 94-220 <0.001 129 50-166 182 135-330 <0.001 
LDL (mg/dL) 23.5 12-
154 
75.5 16-165 <0.001 200 160-272 230 124-340 0.004 
HDL (mg/dL) 55 52-59 50 44-52 <0.001 55 48-57 47 38-55 <0.001 
 




CAD has been considered one of the 
extra gastrointestinal diseases associated with 
H. pylori infection (18). In this study designed 
to determine, by serology, association between 
H. pylori and CAD, the cases were carefully 
matched for age, gender and important risk 
factors for CAD such as history of smoking, 
hypertension and diabetes mellitus, with the 
controls. In our study, H. pylori IgG was high 
in both case and control groups (p=0.346). 
Studies done on the association between H. 
pylori infection and cardiovascular diseases 
have been mostly carried out with the 
serological H. pylori IgG test because it is 
rapid, inexp- ensive and non-invasive (19, 20). 
However, there have been contradictory 
reports between serology and occurrence of 
CAD. While some researchers have reported 
non-significant association between H. pylori 
seropositivity and CAD (21,22), others have 
reported sign- ificant association (19,20). 
These conflicting reports may be explained by 
the fact that antibody testing cannot 
differentiate recent and past infection (23). 
Therefore, serological test is usually performed 
to study only association between the 
occurrence of H. pylori infection and CAD (19). 
 In this study, CagA IgG was signifi- 
cantly detected in cases more than controls 
(p=0.028), and there was significant asso- 
ciation of H. pylori and Cag A IgGs in the cases 
(p=0.007) but not in the controls (p=0.700). It 
has been reported that patients with CAD are 
more prone to infection by CagA positive H. 
pylori strains with more vigorous clinical 
manifestations (24). This may be due to the 
exaggerated inflammatory reaction in CagA-
positive H. pylori infection from increased 
systemic levels of interleukin (IL)-1β, IL-6, IL-
8 and tumour necrosis factor-alpha (TNF-α), 
which tend to exert injurious damage to the 
vascular endothelial cells (11). In addition, 
elevated levels of thrombin factor and pro-
thrombin subunits F1+2 in patients with both 
CAD and CagA positive H. pylori strains have 
been reported (25). Moreover, antibodies 
against CagA show cross-reactivity with 
vascular wall antigens, providing a potential 
role of CagA in vascular wall inflammation 
(26).  
The serum HSP60 IgG level in our 
study was significantly higher in cases than in 
controls (p<0.001) and higher anti-HSP60 
antibodies level was significantly associated 
with both H. pylori and CagA IgGs positivity in 
the case but no such significant association in 
the control group. This may suggests an 
association between H. pylori HSP60 and 
development of CAD. Consistent with the 
hypothesis of Wick and coworkers (27), ather-
osclerosis can be associated with high levels of 
HSP antibodies because of an autoimmune 
response directed against endothelial tissue 
expressing high levels of HSP in response to 
traumatic stimuli such as local infections, 
cytokines, elevated LDL, or other stressful 
conditions. Another explanation is that both 
bacterial toxic metabolites and the concomitant 
inflammatory response can change the epith- 
elial HSP such that immune tolerance to self 
HSP is lost, with production of autoantibodies 
which cross-react with H. pylori HSPs (11). 
Latif et al., (28) found a strong similarity bet- 
ween HSP60 and heavy chain of cardiac myo- 
sin, therefore, cross-reaction between related 
epitopes could result in autoimmunity.   
 In our study, H. pylori IgG-positive 
subjects had significantly elevated TG, TC and 
LDL levels and significantly lower HDL level 
than those with H. pylori IgG-negative ones. 
Some researchers have reported that chronic 
H. pylori infection changes the lipid profile. 
Rahman et al., (29) and Lee et al., (30) repor- 
ted significantly lower levels of HDL in patients 
with H. pylori infection with and without CAD. 
Jia et al., (31) reported that H. pylori infection 
may lower HDL levels with predisposition to 
coronary atherosclerosis. Kim et al., (32) also 
reported that LDL cholesterol level was sign- 
ificantly higher in H. pylori infected patients, 
and increasing H. pylori severity increased LDL 
levels, which is the most important risk factor 
for atherosclerosis. Therefore, atherogenic lipid 
(elevated LDL and decreased HDL) profile has 
been reported in H. pylori infected compared to 
un-infected patients (33). However, other 
researchers have reported that lipid profile was 
not affected by H. pylori infection and 
therefore not considered as a risk factor for 
CAD (34). 
Conclusion: 
There is serological evidence that H. 
pylori infection may pose a significant risk 
factor for CAD. Since H. pylori can be 
eliminated by specific treatment, this may be a 
good preventive approach for CAD. 
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